

ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY

A021502 STUDY DOCUMENTS

RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE III COLON CANCER AND DEFICIENT DNA MISMATCH REPAIR (ATOMIC)

ClinicalTrials.gov Identifier: NCT02912559

Study Activation Date: 09/12/2017

Study Closure Date: N/A

Patient Follow-up Termination Date: N/A

DOCUMENT NAME	EFFECTIVE DATE	ALLIANCE POSTING DATE
Activation (NCI Version 07/13/2017) Memorandum Re: Requirements for NDA/Registration Trial	09/12/2017	09/12/2017
Update #01 (NCI Version 11/02/2017) Memorandum Re: Delegation of Task Log Activation		12/15/2017
Update #02 (NCI Version 05/08/2018) Correlative Science Manual		07/15/2018
Update #03 (NCI Version 07/09/2018) Memorandum Re: Delegation of Task Log Revision		08/01/2018
Update #04 (NCI Version 09/21/2018) Atezolizumab Action Letter Broadcast Re: Action Letter: Immediate Action Required		10/05/2018
Update #05 (NCI Version 02/05/2019)		03/01/2019
Update #06 (NCI Version 06/30/2020)		08/01/2020
Update #07 (NCI Version 10/29/2020)		12/15/2020
Update #08 (NCI Version 04/08/2021)		05/01/2021
Updated #09 (NCI Version 06/07/2021) Atezolizumab Action Letter Broadcast Re: Action Letter: Immediate Action Required		06/23/2021
Action Required 06/23/2021 Update #10 (NCI Version 10/15/2021)		12/15/2021
Update #11 (NCI Version 08/01/2022)		09/01/2022
Update #12 (NCI Version 08/25/2022)		10/01/2022
Update #13 (NCI Version 10/11/2022)		12/01/2022